Effectiveness of remdesivir in patients with COVID-19 and severe renal insufficiency: a nationwide cohort study in Japan
In noncritical patients with COVID-19 and severe renal insufficiency at admission, initiating remdesivir early after disease onset, within the first 2 days of admission, led to a lower risk of mortality or IMV/ECMO initiation, compared with non-initiation of remdesivir.
Authors
- Takahiro Itaya (ORCID: https://orcid.org/0000-0002-0560-8686)
- Kayoko Hayakawa (ORCID: https://orcid.org/0000-0002-5480-4405)
- Yusuke Ogawa (ORCID: https://orcid.org/0000-0001-9256-5102)
- Yoshie Yamada (ORCID: https://orcid.org/0000-0002-0424-3750)
- Noriko Iwamoto (ORCID: https://orcid.org/0000-0001-5471-7363)
- Gen Yamada (ORCID: https://orcid.org/0000-0001-9433-4287)
- Michiyo Suzuki (ORCID: https://orcid.org/0000-0002-6207-8474)
- Yosuke Yamamoto
- Norio Ohmagari
Institutions
- Kyoto University (JP)
- National Center for Global Health and Medicine (JP)
- Center for Global Health (US)
Publication Details
- Journal
- Infectious Diseases
- Published
- 2024-10-06
- DOI
- https://doi.org/10.1080/23744235.2024.2409729
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39